Atlas Trials

Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

Clinical trial NCT04850560 · UNKNOWN

Trial details

NCT number
NCT04850560
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Objective Response Rate
Start date
2021-05-18
Primary completion
2022-05-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.